×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GMAB – genmab a/s - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GMAB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/7
07:59 am
gmab
Transactions In Connection with Share Buy-back Program [Yahoo! Finance]
Medium
Report
Transactions In Connection with Share Buy-back Program [Yahoo! Finance]
4/4
08:30 am
gmab
New Chromatography Data Platform Wins Bio-IT World Award for Genmab and Genedata
Low
Report
New Chromatography Data Platform Wins Bio-IT World Award for Genmab and Genedata
4/2
10:11 am
gmab
Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now? [Yahoo! Finance]
Low
Report
Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now? [Yahoo! Finance]
4/1
09:04 am
gmab
Genmab A/S (NASDAQ: GMAB) was downgraded by analysts at Sanford C. Bernstein from a "market perform" rating to an "underperform" rating.
Low
Report
Genmab A/S (NASDAQ: GMAB) was downgraded by analysts at Sanford C. Bernstein from a "market perform" rating to an "underperform" rating.
3/31
11:33 am
gmab
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer [Yahoo! Finance]
Low
Report
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer [Yahoo! Finance]
3/31
11:20 am
gmab
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
Low
Report
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
3/31
09:03 am
gmab
This drug company's silver bullet is currently valued at zero [Yahoo! Finance]
Low
Report
This drug company's silver bullet is currently valued at zero [Yahoo! Finance]
3/27
08:00 am
gmab
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
Low
Report
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/14
Genmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance
6.0%
10/15 Swiss stocks - Factors to watch on October 15 [Reuters] 3.6%
2/19 Genmab A/S (GMAB) Q4 2019 Earnings Call Transcript [The Motley Fool] 3.1%
5/1 Genmab A/S (NASDAQ: GMAB) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 2.8%
1/22 Genmab Announces 2019 Net Sales Figures for DARZALEX® (daratumumab) and Achievement of USD 150 Million Sales Milestone in DARZALEX Collaboration with Janssen 2.4%
2/19 Genmab Publishes 2019 Annual Report 2.0%
10/12 Genmab: A Rising Star In Biotech [Seeking Alpha] 1.5%
12/3 Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 1.4%
11/6 Genmab Announces Financial Results for the First Nine Months of 2019 1.3%
10/16 Genmab A/S (NASDAQ: GMAB) had its price target raised by analysts at HC Wainwright from $24.00 to $25.00. They now have a "buy" rating on the stock. 1.2%
10/15 Swiss stocks - Factors to watch on October 15 [Reuters] 3.6%
2/19 Genmab A/S (GMAB) Q4 2019 Earnings Call Transcript [The Motley Fool] 3.1%
5/1 Genmab A/S (NASDAQ: GMAB) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 2.8%
1/22 Genmab Announces 2019 Net Sales Figures for DARZALEX® (daratumumab) and Achievement of USD 150 Million Sales Milestone in DARZALEX Collaboration with Janssen 2.4%
2/19 Genmab Publishes 2019 Annual Report 2.0%
10/12 Genmab: A Rising Star In Biotech [Seeking Alpha] 1.5%
12/3 Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 1.4%
11/6 Genmab Announces Financial Results for the First Nine Months of 2019 1.3%
10/16 Genmab A/S (NASDAQ: GMAB) had its price target raised by analysts at HC Wainwright from $24.00 to $25.00. They now have a "buy" rating on the stock. 1.2%
TOP News Decliners
3/10
Genmab Announces Appointment of Anthony Mancini to Newly Created Position of Chief Operating Officer
-6.4%
12/11 Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock. -3.3%
2/28 Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -2.6%
2/12 Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock. -2.0%
4/6 Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $27.00 price target on the stock. -2.0%
9/13 Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS -1.4%
9/30 Genmab A/S (NASDAQ: GMAB) was given a new $24.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -1.4%
9/9 Genmab and Tempus Enter into Strategic Collaboration Agreement -1.2%
3/5 Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock. -1.2%
8/12 Genmab A/S (NASDAQ: GMAB) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock. -0.9%
12/11 Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock. -3.3%
2/28 Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -2.6%
2/12 Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock. -2.0%
4/6 Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $27.00 price target on the stock. -2.0%
9/13 Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS -1.4%
9/30 Genmab A/S (NASDAQ: GMAB) was given a new $24.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -1.4%
9/9 Genmab and Tempus Enter into Strategic Collaboration Agreement -1.2%
3/5 Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock. -1.2%
8/12 Genmab A/S (NASDAQ: GMAB) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock. -0.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: